- Home
- ARCT
as 09-12-2025 4:00pm EST
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 320.8M | IPO Year: | N/A |
| Target Price: | $50.88 | AVG Volume (30 days): | 536.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.04 - $25.88 | Next Earning Date: | 11-06-2025 |
| Revenue: | $122,122,000 | Revenue Growth: | -25.47% |
| Revenue Growth (this year): | -34.12% | Revenue Growth (next year): | 31.09% |
Stock Insider Trading Activity of Arcturus Therapeutics Holdings Inc. (ARCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SASSINE ANDY | ARCT | Chief Financial Officer | Aug 15 '25 | Buy | $16.56 | 1,238 | $20,498.80 | 221,764 |
Latest Arcturus Therapeutics Holdings Inc. News
ARCT Breaking Stock News: Dive into ARCT Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
US High Growth Tech Stocks To Watch Now
Business Wire
3 months ago
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Zacks
3 months ago
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Business Wire
3 months ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
MT Newswires
4 months ago
Scotiabank Initiates Arcturus Therapeutics at Outperform
Zacks
4 months ago
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call
GuruFocus.com
4 months ago
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ...
Compare ARCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARCT Arcturus Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.